Lv51
1002 积分 2023-10-17 加入
Second-line tarlatamab improves OS in SCLC
7小时前
已完结
Inside the Mind of the DMC: A Review of Principles and Issues with Case Studies
7天前
已完结
Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms
7天前
已完结
Trial Design and Optimal Determination of CNS Activity of Small Molecule Targeted Therapy in NSCLC
14天前
已关闭
Inside the Mind of the DMC: A Review of Principles and Issues with Case Studies
20天前
已完结
The Path To Tarlatamab Approval: Leveraging Innovative Strategies and Global Regulatory Pathways
21天前
已完结
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
28天前
已完结
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
28天前
已完结
PP01.35 Serplulimab vs atezolizumab added to chemotherapy in patients with treatment-naive ES-SCLC in the United States – ASTRIDE Trial in Progress
1个月前
已完结
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management
1个月前
已完结
皖公网安备34019202002308
